US-based Bridge Pharmaceuticals’ facility in China has been awarded full accreditation by the Council on Accreditation of the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC International).Bridges facility in Beijing (Vital Bridge China) is one of only seven toxicology facilities in China to receive this recognition, and Bridge claims that it is the first US-based company to offer toxicology services in multispecies at both locations in the US and China....   more

US-based Bridge Pharmaceuticals has hired Mr Thomas Oakley as Chief Executive Officer and has promoted Mr Patrik Jeanmonod to the position of Chief Financial Officer. Dr Ronald J Marler has also been appointed as the Chief Scientific Officer of the company. Bridge is a global leader in pre-clinical contract research services with facilities in the US and China...   more

Bridge Laboratories will bolster its China operations again after scoring itself a further $18m worth of venture capital funding. The money will be put towards expanding its toxicology lab in Beijing, in addition to further growing its US operations, which consists of a headquarters in California and a facility in Maryland....   more

Bridge Laboratories announced today that the FDA has accepted data submitted from its Beijing facility on behalf of a US biotech client. The Good Laboratory Practices (GLP) nonhuman primate toxicology study data was generated and submitted last month as part of an IND package to the FDA. Bridge’s Beijing facility was purpose built to conduct GLP studies in support of worldwide regulatory submission – this goal has now been fully realized. “The FDA’s acceptance of this data validates the wisdom of conducting preclinical research in China for clients looking to complete studies economically,” said Tom Oakley, President and CEO, Bridge Laboratories. “We are pleased about what this says about the quality of our work in China – that it clearly meets Western standards – and what it means to companies seeking cost-effective GLP IND-enabling work,” Oakley continued. Foreseeing the opportunity for China-based GLP-compliant preclinical services several years ago, Bridge Laboratories began planning a preclinical services laboratory located in Beijing’s Zhongguancun Life Science Park. This state-of-the-art laboratory, the first in China built from the ground up to meet international GLP-compliant standards, opened in 2006. Bridge recently announced that they are in the process of developing a second facility which is expected to be completed in late fourth quarter 2009. The new facility will be adjacent to the existing one in Beijing, will quadruple the available laboratory space, and will allow Bridge to continue to expand their service offerings for clients worldwide. About Bridge Laboratories Bridge Laboratories is a US-owned, preclinical contract research organization (CRO) that provides US-level regulatory compliant drug development services globally. Bridge is headquartered in Gaithersburg, Maryland, with AAALAC accredited lab facilities in the US and Beijing, China. Bridge is known for its extensive work in toxicology; including vaccines, developmental and reproductive toxicology, and safety pharmacology. Bridge’s facility in China was among the first labs to perform GLP studies for clients worldwide. Bridge’s existing facility in Beijing is the first Asian preclinical CRO with western-level attention to detail and includes one of the largest and most sophisticated animal vivariums in China. This facility was designed from the ground up to be both AAALAC multi-species accredited and US-level GLP compliant....   more

Bridge Laboratories announced today that Haijun (Lou) Dong, PhD and MBA, joined the company as the General Manager in Bridge’s Beijing, China, facility effective April 10, 2009...   more

Pharmaron Holdings Limited, today announced it completed the acquisition of Bridge Laboratories China....   more